To read the full story, subscribe or sign in.

Guilford Licenses Inhibitor Class To Pfizer As Part Of Broad Deal

May 9, 2003

Guilford Pharmaceuticals Inc. is licensing an entire class of potential neurodegenerative disease drugs to Pfizer Inc. for $5 million up front in a deal that could become much more lucrative down the road. (BioWorld Today)

BioWorld

Today's news in brief

BioWorld

BioWorld briefs for Jan 28, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 28, 2026.

DNA mutations or genetic disorder concept art

Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

BioWorld Science

Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

Muted and missing M&As: JPM deals absent in 2026

BioWorld

For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...